Epigallocatechin gallate attenuates fibroblast proliferation and excessive collagen production by effectively intervening TGF-β1 signalling

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 8, 2015, Pages 849-859

  Sriram, Narayanan ^a   Kalayarasan, Srinivasan ^a   Manikandan, Ramar ^a   Arumugam, Munusamy ^a   Sudhandiran, Ganapasam ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

EGCG; Collagen; Fibroblast; Pulmonary fibrosis; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; HYDROXYPROLINE; TRANSFORMING GROWTH FACTOR BETA1; BLEOMYCIN; CATECHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FIBROBLAST; LUNG FIBROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; WISTAR RAT;

ANIMALS; BLEOMYCIN; CATECHIN; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84957971984     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12428     Document Type: Article

References (40)

1. Chapman HA. Disorders of lung matrix remodeling. J. Clin. Invest. 2004; 113: 148-57.
2. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 2004; 55: 395-417.
3. Artaud-Macari E, Goven D, Brayer S et al. Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2013; 18: 66-79.
4. Cosgrove GP, Brown KK, Schiemann WP et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: A role in aberrant angiogenesis. Am. J. Respir. Crit. Care Med. 2004; 170: 242-51.
5. Xu X, Dai H, Wang C. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: Current status and future directions. Clin. Respir. J. 2014; doi:10.1111/crj.12190 [Epub ahead of print].
6. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur. J. Pharm. Sci. 2014; 58: 13-9.
7. Wojcik KA, Skoda M, Koczurkiewicz P, Sanak M, Czyz J, Michalik M. Apigenin inhibits TGF-beta1 induced fibroblast-to-myofibroblast transition in human lung fibroblast populations. Pharmacol. Rep. 2013; 65: 164-72.
8. Bonniaud P, Margetts PJ, Kolb M et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. 2005; 171: 889-98.
9. de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect. 2006; 19: 85-90.
10. Javelaud D, Mauviel A. Mammalian transforming growth factor-betas: Smad signalling and physio-pathological roles. Int. J. Biochem. Cell Biol. 2004; 36: 1161-5.
11. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005; 19: 2783-810.
12. Dangi-Garimella S, Strouch MJ, Grippo PJ, Bentrem DJ, Munshi HG. Collagen regulation of let-7 in pancreatic cancer involves TGF-beta1-mediated membrane type 1-matrix metalloproteinase expression. Oncogene 2011; 30: 1002-8.
13. Leask A, Abraham DJ. TGF-beta signalling and the fibrotic response. Faseb. J. 2004; 18: 816-27.
14. Andonegui G, Ni A, Leger C et al. Sequential expression of IGF-IB followed by active TGF-beta1 induces synergistic pulmonary fibroproliferation in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 303: L788-98.
15. Harris WT, Muhlebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL. Plasma TGF-beta(1) in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy. Pediatr. Pulmonol. 2011; 46: 688-95.
16. Kobayashi T, Kim H, Liu X et al. Matrix metalloproteinase-9 activates TGF-beta and stimulates fibroblast contraction of collagen gels. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 306: L1006-15.
17. Sriram N, Kalayarasan S, Sudhandiran G. Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chem. Biol. Interact. 2009; 180: 271-80.
18. Sriram N, Kalayarasan S, Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signalling. Pulm. Pharmacol. Ther. 2009; 22: 221-36.
19. Sriram N, Kalayarasan S, Sudhandiran G. Enhancement of antioxidant defense system by epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Biol. Pharm. Bull. 2008; 31: 1306-11.
20. Siddesha JM, Valente AJ, Sakamuri SS et al. Acetylsalicylic acid inhibits IL-18-induced cardiac fibroblast migration through the induction of RECK. J. Cell. Physiol. 2014; 229: 845-55.
21. Selman M, Ruiz V, Cabrera S et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell. Mol. Physiol. 2000; 279: L562-74.
22. Ma Q, Kim EY, Han O. Bioactive dietary polyphenols decrease heme iron absorption by decreasing basolateral iron release in human intestinal Caco-2 cells. J. Nutr. 2010; 140: 1117-21.
23. Weinreb O, Mandel S, Youdim MB, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic. Biol. Med. 2013; 62: 52-64.
24. Cheng XW, Kuzuya M, Kanda S et al. Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic activity without influencing the attachment to extracellular matrix proteins but enhances MMP-2 binding to TIMP-2. Arch. Biochem. Biophys. 2003; 415: 126-32.
25. Li M, Krishnaveni MS, Li C et al. Epithelium-specific deletion of TGF-beta receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J. Clin. Invest. 2011; 121: 277-87.
26. Budinger GR, Mutlu GM, Eisenbart J et al. Proapoptotic Bid is required for pulmonary fibrosis. Proc. Natl Acad. Sci. USA 2006; 103: 4604-9.
27. Xu P, Bailey-Bucktrout S, Xi Y et al. Innate Antiviral Host Defense Attenuates TGF-beta Function through IRF3-Mediated Suppression of Smad Signaling. Mol. Cell 2014; 56: 723-37.
28. Shen ZJ, Braun RK, Hu J et al. Pin1 protein regulates Smad protein signalling and pulmonary fibrosis. J. Biol. Chem. 2012; 287: 23294-305.
29. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005; 111: 2509-17.
30. Zhao J, Shi W, Wang YL et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002; 282: L585-93.
31. Wu MS, Liao CW, Du WY et al. Enhanced expression of transforming growth factor-beta 1 in inflammatory cells, alpha-smooth muscle actin in stellate cells, and collagen accumulation in experimental granulomatous hepatitis caused by Toxocara canis in mice. Acta Trop. 2008; 105: 260-8.
32. Schlaf G, Schmitz M, Heine I, Demberg T, Schieferdecker HL, Gotze O. Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells. Histol. Histopathol. 2004; 19: 1165-74.
33. Wang T, Zhou XT, Yu Y et al. Expression of Smad7 inhibits fibrogenic responses of keratocytes to transforming growth factor beta2. Chin. Med. J. (Engl) 2011; 124: 1988-93.
34. Nakao A, Fujii M, Matsumura R et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest. 1999; 104: 5-11.
35. Mandel S, Weinreb O, Amit T, Youdim MB. Cell signalling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: Implications for neurodegenerative diseases. J. Neurochem. 2004; 88: 1555-69.
36. Gong LK, Li XH, Wang H et al. Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats. J. Ethnopharmacol. 2005; 96: 537-44.
37. Mu D, Cambier S, Fjellbirkeland L et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 2002; 157: 493-507.
38. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises? Int. J. Mol. Sci. 2011; 12: 5592-603.
39. Neuman RE, Logan MA. The determination of collagen and elastin in tissues. J. Biol. Chem. 1950; 186: 549-56.
40. Neely AN, Brown RL, Clendening CE, Orloff MM, Gardner J, Greenhalgh DG. Proteolytic activity in human burn wounds. Wound Repair Regen. 1997; 5: 302-9.